22 January 2021 - The evidence suggests that inclisiran can substantially lower LDL-C with limited safety concerns, and with a ...
22 January 2021 - Public comment period now open until 18 February 2021; requests to make oral comment during public meeting ...
15 January 2021 - The Public Summary Documents (rejections/deferrals/other matters) from the September 2020 PBAC untracycle meeting are now available. ...
21 December 2020 - A plain language summary for the post-market review of the use of biologics in the treatment ...
18 December 2020 - The report on the collection of under co-payment data 2019-20 is now available. ...
17 December 2020 - Today, the U.S. FDA published an update to the “List of Off-Patent, Off-Exclusivity Drugs without an Approved ...
17 December 2020 - Independent appraisal committee determines current evidence is adequate to demonstrate that nadofaragene firadenovec and oportuzumab monatox ...
17 December 2020 - The PBS Expenditure and Prescriptions Report 1 July 2019 to 30 June 2020 is now available. ...
2 December 2020 - In the 16th year of its existence, IQWiG has published its 1,000th report: a dossier assessment ...
20 November 2020 - Independent appraisal committee votes that evidence is adequate to demonstrate clinical superiority of emicizumab over factor ...
13 November 2020 - The Public Summary Documents (first time rejections and deferrals) from the July 2020 PBAC meeting are now ...
12 November 2020 - Public comment period on preliminary draft now open until 11 December 2020; requests to make oral comment ...
6 November 2020 - The evidence has significant limitations, and no firm estimate of net health benefit versus best supportive care ...
6 November 2020 - The available evidence on the benefits of reSET-O, Connections, and DynamiCare has substantial limitations and can ...
30 October 2020 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the July 2020 PBAC ...